• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

    10/15/24 7:22:53 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TYRA alert in real time by email
    SC 13D/A 1 ff3991156_13da3-tyra.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13D
    (RULE 13D - 101)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND
    AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a)
    (Amendment No. 3)*
    Tyra Biosciences, Inc.
    (Name of Issuer)
    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)
    90240B106
    (CUSIP Number)


    Josh La Grange
    Fried, Frank, Harris, Shriver & Jacobson LLP
    801 17th Street, NW, Washington, DC 20006
    202-639-7497
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)


    October 10, 2024
    (Date of Event which Requires Filing of this Statement)
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    CUSIP No. 90240B106

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Boxer Asset Management Inc
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Bahamas
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     0
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     0%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     CO
     
     
     
     





    CUSIP No. 90240B106

     
    1
    NAMES OF REPORTING PERSONS
     
     
     
    Joe Lewis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    United Kingdom
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     0
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     0%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     IN
     
     
     
     

     


    With respect to Joe Lewis and Boxer Asset Management Inc. (“Boxer Management,” and together with Mr. Lewis, the “Reporting Persons”), this amendment (this “Amendment No. 3”) further amends and supplements the statement on Schedule 13D filed on September 24, 2021 (the “Original Filing”) by Boxer Capital, LLC (“Boxer Capital”), Boxer Asset Management Inc. (“Boxer Management”), MVA Investors, LLC (“MVA Investors”), Aaron I. Davis and Mr. Lewis with respect to the Common Stock, par value $0.0001 (the “Common Stock”) of Tyra Biosciences, Inc. (the “Issuer”), as previously amended on June 16, 2022 (“Amendment No. 1”) and February 8, 2024 (“Amendment No. 2”). Amendment No. 1 was an original filing for Siddarth Subramony. On October 10, 2024, Boxer Capital entered into an investment management agreement (the “IMA”) with Boxer Capital Management, LLC (“BCM”), a registered investment advisor controlled by Mr. Davis. Pursuant to the IMA, Boxer Capital has delegated exclusive voting and investment power over its investment portfolio to BCM. Consequently, BCM has acquired beneficial ownership of the securities held in Boxer Capital’s investment portfolio and, without reflecting any change in its economic interest in such securities, Boxer Capital has thereby ceased to beneficially own the securities held in its investment portfolio, including shares of Common Stock. Consequently, each of Boxer Management and Mr. Lewis has ceased to beneficially own the securities held in Boxer Capital’s investment portfolio. Capitalized terms used herein but not defined herein shall have the respective meanings defined in the Original Filing, as previously amended. The Original Filing, as previously amended, is further amended hereby only as specifically set forth herein, provided that with respect to any Item amended herein, if such Item is incorporated by reference into any other Item in the Original Filing, as previously amended, such incorporation by reference is also amended hereby. The Reporting Persons report herein that they have ceased to beneficially own more than 5% of the outstanding shares of Common Stock. On or about the day of this filing, Boxer Capital, MVA Investors, Mr. Davis and Mr. Subramony are independently amending the Original Filing with respect to themselves, which filing is being joined by BCM; see that filing for any required information pertaining to any of them.

    Item 2.
    Identity and Background.

    Item 2 is hereby amended and restated to read as follows:
    This Schedule 13D is jointly filed by Boxer Management and Mr. Lewis.
    Boxer Management, a Bahamian international business company, is the managing member and majority owner of Boxer Capital, a limited liability company organized under the laws of Delaware. Mr. Lewis is the sole indirect owner of and controls Boxer Management. Boxer Management is primarily engaged in the business of investing in securities. Mr. Lewis is a citizen of the United Kingdom and his present principal occupation or employment is engaging in business as a private investor including through the investments of Boxer Capital.
    The address of each of Boxer Management and Mr. Lewis for purposes of this filing is: Albany Financial Center, Suite 207, Lewis Drive, N7776, New Providence, Bahamas.
    Set forth on Schedule A, and incorporated herein by reference, is the (a) name, (b) residence or business address, (c) present principal occupation or employment and (d) citizenship, of each executive officer and director of Boxer Management and (e) name of any corporation or other organization in which such occupation or employment is conducted, together with the principal business and address of any such corporation or organization other than Boxer Management.
    Except as set forth on Schedule B to this Schedule 13D, none of the Reporting Persons nor any of the individuals identified on Schedule A to this Schedule 13D has, during the past five years, (a) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors), or (b) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting, or mandating activities subject to, federal or state securities laws or a finding of any violation with respect to such laws.

    Item 3.
    Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended by the addition of the following:

    The disclosure set forth below in Item 4 is hereby incorporated herein.

    Item 4.
    Purpose of Transaction.

    Item 4 is hereby amended by the addition of the following:

    On October 10, 2024, Boxer Management, Boxer Capital and BCM entered into the IMA, pursuant to which Boxer Capital has delegated exclusive voting and investment power over its investment portfolio to BCM. Consequently, BCM has acquired beneficial ownership of the shares of Common Stock held by Boxer Capital and, without reflecting any change in its economic interest in such securities, Boxer Capital has thereby ceased to beneficially own the securities held in its investment portfolio, including shares of Common Stock. Consequently, each of Boxer Management and Mr. Lewis has ceased to beneficially own the securities held in Boxer Capital’s investment portfolio.







    Item 5.
    Interest in Securities of the Issuer.

    Item 5 is hereby amended and restated to read as follows:
     
    All percentages are based on 52,806,137 shares of the Issuer’s Common Stock outstanding as of August 5, 2024 as set forth in the Issuer’s 10-Q filed with the Securities and Exchange Commission on August 7, 2024.
    (a) The Reporting Persons beneficially own no shares of Common Stock.
    (b) The Reporting Persons have no rights or powers to vote, or to direct the vote of, or to dispose of, or to direct the disposition of, shares of the Common Stock.
    (c) Other than as described herein in Item 4 or transactions previously reported on Form 4, the Reporting Persons have not engaged in any transactions in the Common Stock in the past 60 days.
    (d) Not applicable.
    (e) As described in Item 4, as of October 10, 2024, Boxer Management and Mr. Lewis ceased to beneficially own more than 5% of the outstanding shares of Common Stock.
    Item 7.
    Material to be Filed as Exhibits.

    Item 7 is hereby amended by the addition of the following:

    Exhibit No.
    Description
    Exhibit 3
     
     
    Joint Filing Agreement, dated October 15, 2024, among Boxer Management and Mr. Lewis.
     
     




    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated:  October 15, 2024

     
     
     
     
    BOXER ASSET MANAGEMENT INC.
     
     
     
     
     
    By:
    /s/ Paul Higgs
     
     
     
    Name:
    Paul Higgs
     
     
     
    Title:
    Director
     
     
     
     
     
     
    JOSEPH C. LEWIS
     
     
     
     
     
    /s/ Joseph C. Lewis
     
      
    Joseph C. Lewis, Individually
     
         






    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)
     In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.0001 par value per share, of Tyra Biosciences, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to those joint filings. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein. This agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
    Dated: October 15, 2024.
     
     
     
     
    BOXER ASSET MANAGEMENT INC.
     
     
     
     
     
    By:
    /s/ Paul Higgs
     
     
     
    Name:
    Paul Higgs
     
     
     
    Title:
    Director
     
     
     
     
     
     
    JOSEPH C. LEWIS
     
     
     
     
     
    /s/ Joseph C. Lewis
     
      
    Joseph C. Lewis, Individually
     
         






    SCHEDULE A
    ADDITIONAL INFORMATION CONCERNING THE REPORTING PERSONS

    BOXER ASSET MANAGEMENT INC.
    The executive officers and directors of Boxer Asset Management Inc. are set forth below. Each individual’s business address is Albany Financial Center, Suite 207, Lewis Drive, N7776, New Providence, Bahamas. Except as otherwise stated, the present principal occupation or employment set forth below opposite the name of each person refers to employment with Boxer Asset Management Inc.
     
             
    Name
     
    Present Principal Occupation or Employment
     
    Citizenship
         
    Joe Lewis
     
    Director, President
     
    United Kingdom
         
    Paul Higgs
     
    Director, Vice President
     
    United States




    SCHEDULE B


    On January 24, 2024, Mr. Lewis pled guilty before the Hon. Jessica G.L. Clarke, in the United States District Court for the Southern District of New York, to one count of conspiracy to commit securities fraud and two counts of securities fraud, in violation of 18 U.S.C. § 371, 15 U.S.C. § 78(b) and 78ff. On April 4, 2024, Judge Clarke sentenced Mr. Lewis to three years of probation, a fine of $5 million and a special assessment of $300.

    Separately, on April 3, 2024, Mr. Lewis reached an agreement with the U.S. Securities and Exchange Commission to settle a civil lawsuit brought against him by the Commission in the United States District Court for the Southern District of New York alleging insider trading violations of the federal securities laws. Mr. Lewis agreed to pay a civil penalty of $1,636,645.11 and agreed to be permanently enjoined by the District Court from violating Section 10(b) of the Securities and Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.





    Get the next $TYRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TYRA

    DatePrice TargetRatingAnalyst
    5/21/2025$33.00Overweight
    Piper Sandler
    1/7/2025$28.00Buy
    UBS
    10/18/2024$22.00 → $31.00Neutral → Buy
    BofA Securities
    8/15/2024$33.00Overweight
    Piper Sandler
    12/15/2023$25.00 → $15.00Buy → Neutral
    BofA Securities
    6/30/2023$27.00Outperform
    Wedbush
    2/3/2023$17.00Outperform
    Oppenheimer
    6/23/2022$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $TYRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Tyra Biosciences with a new price target

      Piper Sandler resumed coverage of Tyra Biosciences with a rating of Overweight and set a new price target of $33.00

      5/21/25 9:01:58 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Tyra Biosciences with a new price target

      UBS initiated coverage of Tyra Biosciences with a rating of Buy and set a new price target of $28.00

      1/7/25 8:31:57 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences upgraded by BofA Securities with a new price target

      BofA Securities upgraded Tyra Biosciences from Neutral to Buy and set a new price target of $31.00 from $22.00 previously

      10/18/24 7:41:59 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Financials

    Live finance-specific insights

    See more
    • Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

      - Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity - - Positive safety results across all QD doses, with infrequent FGFR2/FGFR1-associated toxicities - - Conference call scheduled for October 25th, 2024, at 8AM EDT - CARLSBAD, Calif., Oct. 24, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, ann

      10/24/24 6:21:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

      CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentation at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024, in Barcelona, Spain. Gary Ste

      10/23/24 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia

      - In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024--Conference call and webcast today, March 1st, at 8:00 am ET- CARLSBAD, Calif., March 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptors (FGFR) biology, today announced that it is expanding development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results demonstrated in a study performed in collaboration with the Ima

      3/1/23 7:00:00 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

      SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

      12/6/24 9:30:49 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

      SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

      11/19/24 9:31:34 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

      SC 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)

      11/14/24 5:47:01 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Harris Todd was granted 1,241 shares, increasing direct ownership by 0.09% to 1,357,168 units (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      3/18/25 6:44:12 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Fuhrman Alan was granted 1,238 shares, increasing direct ownership by 10% to 14,087 units (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      3/18/25 6:44:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kjellson Nina S sold $74,324 worth of shares (5,401 units at $13.76) (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      2/7/25 4:43:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tyra Biosciences to Participate at Upcoming Investor Conferences

      CARLSBAD, Calif., May 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences: Bank of America Global Healthcare Conference, May 13-15, 2025Format: Fireside chat and one-on-one investor meetingsPresentation Date/Time: Tuesday, May 13, 2025, at 5:15 PM PTLocation: Las Vegas, NVJefferies Global Healthcare Conference, June 3-5, 2025Format: One-on-one investor meetingsLocation: New York, NYUBS Biotech 1x1 Symposium, June 24,

      5/12/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

      - BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment - - Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC) - - Cash, cash equivalents, and marketable securities of $318.9 million at Q1 2025; runway through at least 2027 - CARLSBAD, Calif., May 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress. "In 2025, we are focus

      5/8/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

      - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC), BEACH301 for pediatric achondroplasia (ACH) and SURF301 for metastatic urothelial cancer (mUC) - - Cash, cash equivalents, and marketable securities of $341.4 million at YE 2024; runway through at least 2027 - CARLSBAD, Calif., March 27, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today rep

      3/27/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

      CARLSBAD, Calif., Jan. 29, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Adele Gulfo to its Board of Directors. Ms. Gulfo brings nearly three decades of executive leadership experience to the TYRA board, with a strong track record in developing and commercializing some of the world's best-selling medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma. "Adele is one of the most accomplished drug developers in our industry, with nearly thirty years of global ex

      1/29/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

      -TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2 2025- CARLSBAD, Calif., Jan. 10, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cance

      1/10/25 8:00:00 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

      - Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - - Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30

      11/7/24 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $19,836,066 worth of shares (1,220,681 units at $16.25) (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      11/13/24 5:00:07 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Fuhrman Alan bought $151,954 worth of shares (9,500 units at $16.00), increasing direct ownership by 284% to 12,849 units (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      11/1/24 4:22:45 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    SEC Filings

    See more
    • SEC Form 8-K filed by Tyra Biosciences Inc.

      8-K - Tyra Biosciences, Inc. (0001863127) (Filer)

      5/29/25 4:22:58 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Tyra Biosciences Inc.

      EFFECT - Tyra Biosciences, Inc. (0001863127) (Filer)

      5/19/25 12:15:16 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.

      SCHEDULE 13G - Tyra Biosciences, Inc. (0001863127) (Subject)

      5/14/25 4:05:29 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care